Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

0.74EUR
6:01pm IST
Change (% chg)

€0.00 (+0.27%)
Prev Close
€0.74
Open
€0.72
Day's High
€0.76
Day's Low
€0.72
Volume
56,652
Avg. Vol
187,820
52-wk High
€1.34
52-wk Low
€0.48

Summary

Name Age Since Current Position

Charles Woler

2020 Chairman of the Board

Alexis Rideau

2020 Chief Executive Officer

Julien Coste

2012 Director of Finance & Administration, Member of the Executive Committee

Marie Bezenger

Member of the Executive Committee, Director of Operations

Georges Gaudriault

2017 Chief Scientific Officer, Director of Research & Development, Member of the Executive Committee

Sebastien Enault

Director of Business Development, Member of the Executive Committee

Coralie Martin

2014 Member of the Executive Committee - Marketing, Communication and Investor Relations

Anne Abriat Hemmendinger

2019 Director

Emmanuel Petiot

2019 Director

Christian Pierret

2010 Director, representing Truffle Capital

Philippe Pouletty

59 2017 Director

Herve Brailly

58 2017 Independent Director

Bernard Fanget

2017 Independent Director

Vincent Jarlier

2017 Independent Director

Yannick Pletan

2017 Independent Director

Biographies

Name Description

Charles Woler

Dr. Charles Woler serves as Chairman of the Board of the Company. He is Member of company's Remuneration Committee. He is currently also Chairman at Novellusdx, OCON Medical and Citoxlab SAS as well as Director of Inflamalps and Atlantoc Healthcare and Manager of W.F.S.

Alexis Rideau

Mr. Alexis Rideau serves as Chief Executive Officer of the Company. Alexis RIDEAU has been directly involved in the definition and implementation of the Institute's technology and economic strategy, as well as the valorization of its state-of-the-art technology platforms in the industrial sectors of microbiota, antimicrobials, vaccines and diagnostic. He initiated and implemented structuring partnerships, technologically and financially, with major French and international players (Takeda Pharmaceuticals, Bio-Rad Laboratories, bioMérieux, Boehringer Ingelheim, etc.), SMEs (Kaleido Biosciences Inc., Enterome, MaaT Pharma, LNC Therapeutics, Biofilm Pharma, etc.) and academic institutions (INRAE MetaGenoPolis, Institut Pasteur, CNRS, etc.). Previously, Alexis RIDEAU held various positions in companies operating in the technology and healthcare fields, including support to entrepreneurs, sector analysis and fundraising (Library House Ltd, Bionest Partners and Glaizer Group) and directly in the field, in the conquest of new industrial markets (MorphoSys AG, Bio-Rad Laboratories). Alexis RIDEAU holds a PhD in Molecular and Cellular Biology (University of Cambridge, England), a European Magistère in Genetics and an MSc in Cellular and Molecular Genetics (Paris Diderot University and Sorbonne University), as well as an MBA in International Management (ESCP Europe).

Julien Coste

Mr. Julien Coste has been Director of Finance & Administration and a Member of the Executive Committee of Deinove SA since July 31, 2012. He was Director of Finance and Administration at Neuro3d. More recently, he held the same position for the French branch of Publicis Healthcare Communications Group (PHCG), a division of the Publicis Group. He has a Masters’ degree in Management from ESC Grenoble as well as a Masters’ degree in Information Systems from the University of Paris Dauphine.

Marie Bezenger

Ms. Marie Bezenger is Member of the Executive Board, Director of Operations of Deinove SA. She graduated from Universite de Montpellier with a Doctorate in Biochemistry. She has spent over 20 years at Chr. Hansen Group.

Georges Gaudriault

Dr. Georges Gaudriault has been Chief Scientific Officer, Director of Research & Development, Member of the Executive Committee of the Company since May 16, 2017. Dr. Gaudriault holds PhD in molecular pharmacology, he's expert in the development of new molecules and their formulation. He has spent his entire career in pharmaceutical innovation.

Sebastien Enault

Coralie Martin

Ms. Coralie Martin is Member of the Executive Committee - Marketing, Communication and Investor Relations of Deinove SA. She graduated from INSA Toulouse as an Engineer in biochemistry. She also holds a Masters degree in Marketing and Management from IAE Lyon. She started her career in Laboratoires Pierre Fabre in marketing department before joining bioMerieux.

Anne Abriat Hemmendinger

Emmanuel Petiot

Mr. Emmanuel Petiot has been appointed as Director of the Company effective 12/31/2019. He is no longer as Chief Executive Officer and Member of the Executive Committee of the Company Effective December 31, 2019. Mr. Petiot joined Air Liquide where he held various marketing and sales functions (1996-2000). He then joined Dow Chemical (2000-2004) before joining Novozymes. In nine years (2004-2012) he had several executive positions in marketing, sales and development of industrial partnerships in Europe, the USA and Asia. He was CEO of the French subsidiary of Novozymes that provided operational support group for all of Europe. Before joining Deinove SA, he was Commercial Director of Novozymes North America Inc. He is a graduate of EDHEC Business School and Ecole Centrale de Paris.

Christian Pierret

Mr. Christian Pierret has been Director of Deinove SA since January 27, 2010, representing Truffle Capital. He is Chairman of company's Audit Committee. Mr. Pierret holds a post-graduate Diploma in economic sciences (1970) and is a graduate of the Ecole Nationale d’Administration (1972). He previously served as Rapporteur General for the budget at the French House of Representatives (Assemblee Nationale) (1981-1986), Chairman of the Caisse des Depots state savings bank monitoring committee (1988-1993), Vice President of the Accor Group (1993-1996), congressman for The Vosges between 1978 and 1993, Mayor of Saint-Die des Vosges since 1989, and former Minister for Industry, SME’s, Trade and Crafts. In February 2002 he instigated "Pierret Act" which opened the French market to competition in the electricity and telecoms sectors. He wrote the book "Ministre a gauche - le magique et le reel" (Ed. Le Pre-aux-Clercs, 2002) and has published articles in the economic and political press (Les Echos, La Tribune, Le Figaro, Le Monde, Financial Times, etc.).

Philippe Pouletty

Dr. Philippe Pouletty has served as Director at Deinove since January 23, 2017. Prior to this, he was Chairman of the Board at the Company from January 27, 2010. He is Chairman of company's Remuneration Committee. Dr. Pouletty is founder of three biotechnology companies, SangStat, Conjuchem, and DrugAbuse, two of which were launched on the stock market: SangSat (Nasdaq : SANG) went public in 1993 and was subsequently acquired by Genzyme, whereas Conjuchem listed in 2000 (Toronto Stock Exchange: CJB). Dr. Pouletty is former Chairman of France Biotech, the French Biotechnology Industry Association and former Vice-Chairman of Europabio, the European Biotech Industry Association and inventor of 29 patents. He also serves as Director of Carmat, Pharnext, Abivax, Biokinesis and Myopowers,among others. Dr. Pouletty has been made a Knight of the French Legion of Honor (Chevalier de la Legion d’Honneur). He earned a Doctorate of Medicine from the University of Paris VI, Immunologist, and is a graduate of Pasteur Institute in Immunology. Dr. Pouletty served as post-doctoral research fellow at Stanford University and won the 1999 American Liver Foundation Prize. He is a former member of the French Council for Economic Attractiveness “Conseil Strategique pour l’Attractivite de la France”, chaired by the French prime minister.

Herve Brailly

Mr. Herve Brailly, Ph.D., has serves as Independent Director of the Company since May 16, 2017. He co-founded Innate Pharma, one of the first market capitalizations of French biotech. He managed the company for 17 years and was appointed chairman of its supervisory board.

Bernard Fanget

Mr. Bernard Fanget has been Independent Director of Deinove SA since January 20, 2017. He is currently also Chairman of Neostell SAS as well as of Bernard Fanget Consulting SA.

Vincent Jarlier

Yannick Pletan

Mr. Yannick Pletan has been Independent Director of Deinove SA since January 20, 2017. Mr. Pletan is Member of company's Audit Committee. He is currently also Chief Executive Officer at Ultrace Development Partner.